

Media contact: Reese A. Nank, APR • 410-218-9121 • reputationspr@cox.net
Company contact: Mark Keck, Vice President, Marketing • T: 216-332-1665 x106 • mkeck@chantest.com

FOR IMMEDIATE RELEASE

ChanTest To Hold Free Webinar on Stem Cell-Derived Human Cardiomyocyte Assays in Cardiac Risk Evaluation

Feb. 4, 2010, CLEVELAND – ChanTest has developed a new stem cell-derived human cardiomyocyte (SC-hCM) action potential assay for improved cardiac risk evaluation of drug candidates in pre-clinical development. On Thursday, February 11 at 11:00 a.m. EST the company will host a free webinar to explain the advantages in sensitivity and cost of the new assay as compared to conventional non-human Purkinje fiber assays (PF).

Andrew Bruening-Wright, Ph.D, Project Director at ChanTest, will provide a comprehensive overview on the validation and benefits of the SC-hCM action potential assay.

Arthur “Buzz” Brown, founder, president and CEO of ChanTest said, “For anyone conducting a Thorough Pre-clinical Cardiac Risk Assessment program, the information provided in our webinar is critical to preventing torsadogenic compounds that are negative in PF assays from advancing to clinical trials.”

To register for the webinar, check the New & Events section on the Chantest website or go to <https://www2.gotomeeting.com/register/245221955>.

About ChanTest Corporation (www.chantest.com)

ChanTest’s mission is to serve the research, drug discovery and drug development needs of customers worldwide with high-value solutions for ion channel and GPCR biology. Since its inception in 1998, the company has tested compounds for more than 500 global pharmaceutical and biotechnology companies and partners with them to speed the drug development process for the release of better, safer drugs. ChanTest offers integrated ion channel and GPCR services (GLP and non-GLP) and reagents; the company’s library of validated ion channel cell lines and pre-clinical cardiac risk assessment service portfolio are the most comprehensive commercially available today. Because of ChanTest’s seminal role in the pre-clinical cardiac safety field, along with the company’s uncompromising commitment to quality, ChanTest has been named the “most trusted and most used fee-for-service provider” for ion channel screening in an independent survey for the past three years. ChanTest is based in Cleveland, Ohio. For more information, e-mail info@chantest.com.

###